EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Omiganan Pentahydrochloride in the Front Line of Clinical Applications of Antimicrobial Peptides

Manuel N Melo, Dominique Dugourd, Miguel A R B Castanho

Recent Patents on Anti-Infective Drug Discovery · 2006

DOI: 10.2174/157489106777452638 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Anti-Infective Drug Discovery, 2006. Verfasst von Manuel N Melo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande C8, 1749-016 Lisboa, Portugal. Die Arbeit wurde bisher 70-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ribosomally synthesized antimicrobial peptides have very wide killing spectra and bacterial resistance to these peptides seems to be a rare phenomenon. Indolicidin is a ribosomally synthesized antimicrobial peptide that served as a template to omiganan, which is in development for the prevention of catheter-related bloodstream infections; clinical trials also proved its efficiency against acne vulgaris. Omiganan is the most advanced molecule in the front line of clinical applications of antimicrobial peptides. The mode and site of action of omiganan are not yet settled although its interaction with membranes is known to play a fundamental role. The biochemical and biophysical foundations for the action of indolicidin and its analogues are reviewed in this paper, as well as the clinical application of omiganan. The in vitro efficiency tests and the outcome of clinical trials are addressed. Altogether, despite the very specific use of omiganan as a topical antibiotic, it has the potential of being a pioneer of a new generation of antibiotics that carry the promise of ending the multi-resistance problem.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acne VulgarisAnti-Infective AgentsAntimicrobial Cationic PeptidesBacteriaBacterial InfectionsCatheterizationClinical Trials as TopicHumansPatents as Topic

Substanzen

Anti-Infective AgentsAntimicrobial Cationic Peptidesindolicidinomiganan pentahydrochloride

Autor:innen und Institutionen

  • Centro de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande C8, 1749-016 Lisboa, Portugal.

Zitieren

APA

Melo, M. N., Dugourd, D., & Castanho, M. A. (2006). Omiganan Pentahydrochloride in the Front Line of Clinical Applications of Antimicrobial Peptides. Recent Patents on Anti-Infective Drug Discovery. https://doi.org/10.2174/157489106777452638

Vancouver

Melo MN, Dugourd D, Castanho MA. Omiganan Pentahydrochloride in the Front Line of Clinical Applications of Antimicrobial Peptides. Recent Patents on Anti-Infective Drug Discovery. 2006. doi:10.2174/157489106777452638

BibTeX
@article{Melo2006,
  author = {Melo, Manuel N and Dugourd, Dominique and Castanho, Miguel A R B},
  title = {Omiganan Pentahydrochloride in the Front Line of Clinical Applications of Antimicrobial Peptides},
  journal = {Recent Patents on Anti-Infective Drug Discovery},
  year = {2006},
  doi = {10.2174/157489106777452638}
}
Kostenlos starten →